Ryan Gentzler, MD
Medical Oncology · Charlottesville, VANPI 1235390444
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $53,421 of the $61,784 with a category attached, or 86.5%. 19 manufacturers reported payments, led by AstraZeneca at 37.2% of the total. Among medical oncology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 59 payments — averaging $1047.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$23K
- Pfizer$6K
- Daiichi Sankyo Inc.$5K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Boehringer Ingelheim$4K
- Regeneron$3K
- plus $19K from 13 others
Across 322 payments — averaging $17,075 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.5M
- Amgen$1.5M
- Janssen Research & Development, LLC$897K
- Takeda Pharmaceuticals U.S.A., Inc.$469K
- Pfizer$342K
- AstraZeneca$229K
- plus $583K from 8 others
What the payments were for
- Consulting fees$53,42186%
- Speaking & faculty fees$4,2567%
- Travel & lodging$2,2624%
- Food & beverage$1,7403%
- Education$1050%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $22,995 |
| Pfizer | 5 | $5,700 |
| Daiichi Sankyo Inc. | 4 | $4,729 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $3,608 |
| Boehringer Ingelheim | 1 | $3,553 |
| Regeneron | 5 | $2,675 |
| Gilead | 1 | $2,570 |
| Merck | 5 | $2,546 |
| Sanofi | 1 | $2,289 |
| Blueprint Medicines Corporation | 1 | $2,256 |
| Amgen | 2 | $2,179 |
| Genentech USA, Inc. | 3 | $1,901 |
| Janssen Scientific Affairs, LLC | 1 | $1,768 |
| Jazz Pharmaceuticals Inc. | 1 | $1,400 |
| AbbVie | 2 | $1,088 |
| Astrazeneca UK Limited | 4 | $292 |
| Tempus AI, Inc | 1 | $146 |
| Regeneron Healthcare Solutions, Inc. | 1 | $48 |
| Taiho Oncology, Inc. | 1 | $42 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,784 in reported general payments places this provider in the 90th percentile of 95 medical oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 63 | $996,690 |
| AlecensaAlectinib Hcl | 12 | $199,039 |
| EliquisApixaban | 20 | $16,303 |
| Octreotide Acetate | 13 | $16,256 |
| Ondansetron Hcl | 43 | $848 |
| Fluticasone Propionate | 12 | $682 |
| Dexamethasone | 32 | $457 |
| Prochlorperazine Maleate | 31 | $346 |
| Oxycodone Hcl | 11 | $110 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $22,995 | $996,69063 claims |
| Genentech USA, Inc.Alecensa | $1,901 | $199,03912 claims |
| PfizerEliquis | $5,700 | $16,30320 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 95 medical oncology providers in Virginia.
Other medical oncology in Charlottesville
- Robert DreicerCharlottesville$296K
- Matthew ReilleyCharlottesville$37K
- Enrica MarchiCharlottesville$30K
- Richard HallCharlottesville$29K
- Paul ViscuseCharlottesville$12K
- Ludimila CavalcanteCharlottesville$7K
- William SkeltonCharlottesville$6K
- Paul KunkCharlottesville$4K
- John WagnerCharlottesville$1K
- Patrick DillonCharlottesville$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.